Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Core Insights - Lung cancer remains a critical area of unmet need despite advances in treatment options, with the disease being the leading cause of cancer deaths in the U.S. [4][11] - The Lung Cancer Genetics Study aims to enhance research by collecting genetic, clinical, and patient-reported data to improve detection, risk reduction, and care for lung cancer patients [8][11] Company Overview - 23andMe Holding Co. is a genetic health and biopharmaceutical company that collaborates with 20 lung cancer advocacy organizations to conduct the Lung Cancer Genetics Study [4][9] - The study will utilize the 23andMe research platform to gather critical data from participants, which will be made available to approved researchers at no cost [5][12] Study Details - The study aims to recruit 10,000 individuals diagnosed with lung cancer, with no restrictions on cancer type, stage, gender, or smoking status [14] - Participants will receive 23andMe kits at no cost, and the study seeks to reflect the diversity of communities affected by lung cancer [8][14] Research Goals - The study intends to fill a gap in comprehensive databases that connect genetic, clinical, and patient-reported data, ultimately improving treatment and care for lung cancer [8][11] - It is estimated that in 2024, 234,000 new lung cancer cases will be diagnosed in the U.S., highlighting the urgent need for research [11]